320 related articles for article (PubMed ID: 29093248)
1. [Effect of cinacalcet combined with low-dose calcitriol on clinical outcome and bone metabolism in patients with severe secondary hyperparathyroidism].
Yuan F; Chen X; Wang C; Zhou A; Liu H
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2017 Oct; 42(10):1169-1173. PubMed ID: 29093248
[TBL] [Abstract][Full Text] [Related]
2. Effect of Cinacalcet Combined with Calcitriol on the Clinical Outcome and Bone Metabolism in Patients on Hemodialysis with Severe Secondary Hyperparathyroidism.
Yuan F; Chen X; Wang C; Li Z; Liu H
Blood Purif; 2018; 45(1-3):73-78. PubMed ID: 29216631
[TBL] [Abstract][Full Text] [Related]
3. Cholecalciferol Additively Reduces Serum Parathyroid Hormone Levels in Severe Secondary Hyperparathyroidism Treated with Calcitriol and Cinacalcet among Hemodialysis Patients.
Zheng CM; Wu CC; Hung CF; Liao MT; Shyu JF; Hsu YH; Lu CL; Wang YH; Zheng JQ; Chang TJ; Lin YF; Lu KC
Nutrients; 2018 Feb; 10(2):. PubMed ID: 29439405
[TBL] [Abstract][Full Text] [Related]
4. The impact of cinacalcet in the mineral metabolism markers of patients on dialysis with severe secondary hyperparathyroidism.
Bucharles SGE; Barreto FC; Riella MC
J Bras Nefrol; 2019 Jul; 41(3):336-344. PubMed ID: 31419274
[TBL] [Abstract][Full Text] [Related]
5. Effects of 22-oxacalcitriol and calcitriol on PTH secretion and bone mineral metabolism in a crossover trial in hemodialysis patients with secondary hyperparathyroidism.
Ogata H; Koiwa F; Shishido K; Takahashi K; Ito H; Kinugasa E; Taguchi S
Ther Apher Dial; 2007 Jun; 11(3):202-9. PubMed ID: 17498002
[TBL] [Abstract][Full Text] [Related]
6. Effect of paricalcitol on mineral bone metabolism in kidney transplant recipients with secondary hyperparathyroidism.
Borrego Utiel FJ; Bravo Soto JA; Merino Pérez MJ; González Carmelo I; López Jiménez V; García Álvarez T; Acosta Martínez Y; Mazuecos Blanca MA
Nefrologia; 2015; 35(4):363-73. PubMed ID: 26306956
[TBL] [Abstract][Full Text] [Related]
7. Comparison of oral falecalcitriol and intravenous calcitriol in hemodialysis patients with secondary hyperparathyroidism: a randomized, crossover trial.
Ito H; Ogata H; Yamamoto M; Takahashi K; Shishido K; Takahashi J; Taguchi S; Kinugasa E
Clin Nephrol; 2009 Jun; 71(6):660-8. PubMed ID: 19473635
[TBL] [Abstract][Full Text] [Related]
8. The effectiveness of cinacalcet: a randomized, open label study in chronic hemodialysis patients with severe secondary hyperparathyroidism.
Susantitaphong P; Vadcharavivad S; Susomboon T; Singhan W; Dumrongpisutikul N; Jakchairoongruang K; Eiam-Ong S; Praditpornsilpa K
Ren Fail; 2019 Nov; 41(1):326-333. PubMed ID: 31014177
[TBL] [Abstract][Full Text] [Related]
9. [German observational trial on secondary hyperparathyroidism therapy with cinacalcet (EARLY)].
Reichel H; Braun J
Dtsch Med Wochenschr; 2011 Jan; 136(4):123-8. PubMed ID: 21181622
[TBL] [Abstract][Full Text] [Related]
10. Comparison between calcitriol and calcitriol plus low-dose cinacalcet for the treatment of moderate to severe secondary hyperparathyroidism in chronic dialysis patients.
Lee YT; Ng HY; Kuo CC; Chen TC; Wu CS; Chiu TT; Lee WC; Lee CT
Nutrients; 2013 Apr; 5(4):1336-48. PubMed ID: 23603995
[TBL] [Abstract][Full Text] [Related]
11. Paricalcitol treatment of secondary hyperparathyroidism in hemodialysis patients: a German-Austrian, single-arm, open-label, prospective, noninterventional, observational study.
Biggar P; Kovarik J; Klauser-Braun R; Graf H; Müller HW; Veres A; Seidinger S; Ketteler M
Nephron Clin Pract; 2014; 126(1):39-50. PubMed ID: 24458019
[TBL] [Abstract][Full Text] [Related]
12. Cinacalcet reduces plasma intact parathyroid hormone, serum phosphate and calcium levels in patients with secondary hyperparathyroidism irrespective of its severity.
Frazão JM; Messa P; Mellotte GJ; Geiger H; Hagen EC; Quarles LD; Kerr PG; Baños A; Dehmel B; Urena P
Clin Nephrol; 2011 Sep; 76(3):233-43. PubMed ID: 21888861
[TBL] [Abstract][Full Text] [Related]
13. Paricalcitol- or cinacalcet-centred therapy affects markers of bone mineral disease in patients with secondary hyperparathyroidism receiving haemodialysis: results of the IMPACT-SHPT study.
Cozzolino M; Ketteler M; Martin KJ; Sharma A; Goldsmith D; Khan S
Nephrol Dial Transplant; 2014 Apr; 29(4):899-905. PubMed ID: 24500308
[TBL] [Abstract][Full Text] [Related]
14. [Effect of calcitriol on secondary hyperparathyroidism].
Xu H; Zhang J; Cheng X; Zhou Q
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2013 Sep; 38(9):920-4. PubMed ID: 24071691
[TBL] [Abstract][Full Text] [Related]
15. Cinacalcet for managing secondary hyperparathyroidism in dialysis patients in clinical practice in Belgium: a 16-month observational study (ECHO-B).
Debelle F; Meeus G; Dratwa M; Maes B; Vanholder R; Albert A; Schutyser E; Jadoul M
Acta Clin Belg; 2013; 68(4):275-81. PubMed ID: 24455797
[TBL] [Abstract][Full Text] [Related]
16. [Secondary hyperparathyroidism and anemia. Effects of a calcimimetic on the control of anemia in chronic hemodialysed patients. Pilot Study].
Mpio I; Boumendjel N; Karaaslan H; Arkouche W; Lenz A; Cardozo C; Cardozo J; Pastural-Thaunat M; Fouque D; Silou J; Attaf D; Laville M
Nephrol Ther; 2011 Jul; 7(4):229-36. PubMed ID: 21353659
[TBL] [Abstract][Full Text] [Related]
17. Effects of Denosumab and Calcitriol on Severe Secondary Hyperparathyroidism in Dialysis Patients With Low Bone Mass.
Chen CL; Chen NC; Liang HL; Hsu CY; Chou KJ; Fang HC; Lee PT
J Clin Endocrinol Metab; 2015 Jul; 100(7):2784-92. PubMed ID: 25955225
[TBL] [Abstract][Full Text] [Related]
18. Cinacalcet lowers FGF-23 level together with bone metabolism in hemodialyzed patients with secondary hyperparathyroidism.
Hryszko T; Brzosko S; Rydzewska-Rosolowska A; Koc-Zorawska E; Mysliwiec M
Int Urol Nephrol; 2012 Oct; 44(5):1479-86. PubMed ID: 21874285
[TBL] [Abstract][Full Text] [Related]
19. Anti-parathyroid treatment effectiveness and persistence in incident haemodialysis patients with secondary hyperparathyroidism.
de Francisco AL; Gillespie IA; Gioni I; Floege J; Kronenberg F; Marcelli D; Wheeler DC; Froissart M; Drueke TB;
Nefrologia; 2016; 36(2):164-75. PubMed ID: 26654696
[TBL] [Abstract][Full Text] [Related]
20. Paricalcitol versus cinacalcet plus low-dose vitamin D for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: study design and baseline characteristics of the IMPACT SHPT study.
Ketteler M; Martin KJ; Cozzolino M; Goldsmith D; Sharma A; Khan S; Dumas E; Amdahl M; Marx S; Audhya P
Nephrol Dial Transplant; 2012 May; 27(5):1942-9. PubMed ID: 21931122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]